| Authors: |
Franzoi MA; Cancer Survivorship Group, Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France. mariaalice.borinelli-franzoi@gustaveroussy.fr.; Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France. mariaalice.borinelli-franzoi@gustaveroussy.fr., Santolaya C; Cancer Survivorship Group, Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.; Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France., Martin E; Cancer Survivorship Group, Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France., Fasse L; Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France.; Laboratory of Psychopathology and Health Processes, Paris Cité University, Paris, France., Rouby P; Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France., Minot-This MS; Department of Medical Oncology, Gustave Roussy, 94800, Villejuif, France., Di Meglio A; Cancer Survivorship Group, Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France., Vaz-Luis I; Cancer Survivorship Group, Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.; Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France. |
